Law Enforcement Resources
Effective implementation of laws, policies, and programs often falls on law enforcement agencies. Learn about the available guidance.
Drug and Chemical Information, Drug Enforcement Administration
The Drug Enforcement Administration’s (DEA) Office of Diversion Control maintains a comprehensive list of drugs and chemicals, including information such as trade names, licit and illicit uses, chemistry and pharmacology, and control status. Find specific information on opioids, including Fentanyl, Hydrocodone, Oxymorphone, Oxycodone, and Tramadol.
Drugs of Abuse, A DEA Resource Guide: 2015 Edition
DEA’s resource guide is designed to be a reliable resource on the most commonly abused and misused drugs in the United States. This comprehensive guide provides important information about the harms and consequences of drug use.
DEA Announces “360 Strategy” to Address Heroin, Prescription Drugs and Violent Crime
This press release published on November 10, 2015 describes the DEA’s law enforcement and prevention program to help cities dealing with a heroin and prescription drug abuse epidemic.
DEA “360 Strategy” Fact Sheet
A fact sheet describing DEA’s 360 strategy to break the cycle of drug trafficking, drug violence, and drug abuse.
Call to Action and Issue Brief: Justice System Use of Prescription Drug Monitoring Programs— Addressing the Nation’s Prescription Drug and Opioid Abuse Epidemic
This guidance from the Bureau of Justice Assistance is directed toward justice practitioners and policymakers and serves as an educational resource and call to action.
2015 COPS Anti-Heroin Task Force Program
This fact sheet provides information about a grant program that provides funding to state law enforcement agencies to investigate illicit activities related to the distribution of heroin or unlawful distribution of prescriptive opioids.
Law Enforcement Naloxone Toolkit
The Bureau of Justice Assistance's Law Enforcement Naloxone Toolkit is a clearinghouse of resources to support law enforcement agencies in establishing a naloxone program.
Prescription Drug Fraud and Misuse
This guide from the Center for Problem-Oriented Policing describes the problem of prescription drug fraud and misuse, reviews some of the factors that increase their risks, identifies a series of questions to analyze local problems, and reviews responses to the problem.
Webinar: The Opioid Epidemic- Facts, Trends and Prosecutor-Led Community Responses
On June 8, 2015, the Office of National Drug Control Policy (ONDCP) and the National District Attorneys Association (NDAA) co-hosted a webinar for NDAA members to share important information on the Nation’s opioid epidemic. Topics include the implementation of Naloxone programs, establishing drug take-back operations, and linking their programs to treatment.
Medicaid Fact Sheet: Mental Health and Substance Use Disorder Parity Final Rule for Medicaid and CHIP
A fact sheet from the Centers for Medicare and Medicaid (CMS) describing the final rule, which requires that all beneficiaries who receive services through managed care organizations, alternative benefit plans, or CHIP be provides access to mental health and substance use disorder benefits that comply with parity standards, regardless of whether those services are provided through the managed care organization or another service delivery system.
CMS finalizes mental health and substance use disorder parity rule for Medicaid and CHIP
This March 29, 2016 press release from CMS announced the final parity rule, which strengthens access to mental health and substance use disorder benefits for low-income Americans.
